Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease

William G. Ondo, Christine Hunter, Stuart H. Isaacson, Dee E. Silver, R. Malcolm Stewart, James W. Tetrud, Anthony Davidson

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Selegiline is a monoamine-B specific inhibitor used to treat Parkinson's disease. A Zydis sublingual preparation has more efficient absorption and less first pass amphetamine metabolites. We conducted an open label oral to Zydis switch study to evaluate tolerability of rapid switch, and relative efficacy, in 48 subjects from 5 sites. Overall patients preferred the Zydis preparation. Per clinician global impressions, fluctuations improved and the "on" UPDRS part II scores improved. Total UPDRS and measures of fatigue and sleep were unchanged. Adverse events were mild. Patients generally preferred the Zydis selegiline preparation but the modest difference is of unclear clinical significance given the open label nature of the trial.

Original languageEnglish (US)
Pages (from-to)117-118
Number of pages2
JournalParkinsonism and Related Disorders
Volume17
Issue number2
DOIs
StatePublished - Feb 2011

Keywords

  • Clinical trials
  • Parkinson's disease
  • Selegiline
  • Zydis selegiline

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease'. Together they form a unique fingerprint.

Cite this